Incyte (INCY)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$118.05+2.10%
Close 2026-07-07 · 1-day change
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading INCY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track INCY free→Incyte grows total net sales 20% year-over-year to $1.27B in Q1 2026. Jakafi sales rose 7% to $758M and Opzelura sales grew 20% to $143M. Management targets 2026 revenue near $840M for the full year. Profit margins remain stable with controlled R&D and SG&A expenses near $3.3B. The recent acquisition of Vega Therapeutics expands the pipeline and supports future growth.
Incyte missed EPS estimates in Q4 2025 with a 6.2% shortfall. R&D expenses rose 18% in Q1 2026, pressuring margins. FDA rejection of Zynyz supplemental application limits growth. The acquisition integration risks could delay benefits. Revenue growth slowing below the 10.5% consensus would weaken the thesis.
The market prices in about 10.5% revenue growth and values shares roughly 15% below our $138 fair value. Our fair value is 31% above the Street median of $106, reflecting confidence in Incyte's growth and margin control. We see upside if Incyte sustains its 20% Q1 sales growth and successful pipeline expansion.
Breaks if: expenses exceed $3.38B in FY26
Control research and development and selling, general and administrative expenses while investing in late-stage pipeline
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 6 of last 6 quarters. GAAP R&D expenses rose from $437M in 2025-Q1 to $516M in 2026-Q1 (+18%), SG&A expenses increased slightly from $326M to $328M (+1%). 2026 guidance targets total Non-GAAP R&D and SG&A expenses between $3.205B and $3.375B. Management maintains focus on expense control while investing in pipeline, trajectory shows moderate expense growth consistent with stated priorities.
“GAAP R&D expenses $515.9M, SG&A $328.1M in Q1 2026, increases of 18% and 1% respectively vs prior year.”
“GAAP R&D expenses $611.4M, SG&A $390.4M in Q4 2025, increases of 31% and 19% respectively vs prior year.”
“GAAP R&D expenses $506.6M, SG&A $329.1M in Q3 2025, decreases of 12% and increase of 6% respectively vs prior year.”
“GAAP R&D expenses $494.9M, SG&A $331.0M in Q2 2025, decreases and increases vs prior year.”
“GAAP R&D expenses $437.3M, SG&A $325.7M in Q1 2025, increases vs prior year.”
“GAAP R&D expenses $466.0M, SG&A $326.7M in Q4 2024, increases vs prior year.”
Breaks if: acquisition integration delays or pipeline setbacks reported
Complete the acquisition of Vega Therapeutics to enhance pipeline and R&D capabilities
Newly stated in 2026-Q2. The acquisition of Vega Therapeutics was completed on July 6, 2026 as announced in a press release. This is a strategic growth initiative recently completed and no financial impact is yet reported in the quarterly financials.
“Incyte announced completion of acquisition of Vega Therapeutics on July 6, 2026.”
Breaks if: any product line growth falls below half of target growth rates
Drive growth in Jakafi, Opzelura, and Hematology/Oncology portfolio including Niktimvo, Monjuvi/Minjuvi, and Zynyz
Stated as a priority in 6 of last 6 quarters. Total net sales grew from $1.05B in 2025-Q1 to $1.27B in 2026-Q1 (+20%). Jakafi sales increased 7% to $758M, Opzelura 20% to $143M, and Hematology/Oncology portfolio 116% to $204M in the latest quarter. Management consistently emphasizes growth in these key product lines and the financials show delivering growth across the portfolio.
“Total net sales for Q1 2026 increased 20% driven by Jakafi, Opzelura, and Hematology/Oncology portfolio.”
“Total net product revenue for Q4 2025 increased 20% driven by Jakafi, Opzelura, Niktimvo, and Zynyz.”
“Net product revenues increased 19% driven by Jakafi and strong uptake of Niktimvo.”
“Jakafi net product revenues up 8% and Niktimvo net product revenues demonstrate strong commercial execution.”
“Jakafi net product revenues up 24% and Niktimvo launched with strong execution.”
“Jakafi net revenues up 11% and Opzelura net revenues up 48% in Q4 2024.”
Breaks if: total net sales fall below $3.2B in FY26
Drive growth in Jakafi, Opzelura, and Hematology/Oncology portfolio including Niktimvo, Monjuvi/Minjuvi, and Zynyz
Stated as a priority in 6 of last 6 quarters. Total net sales grew from $1.05B in 2025-Q1 to $1.27B in 2026-Q1 (+20%). Jakafi sales increased 7% to $758M, Opzelura 20% to $143M, and Hematology/Oncology portfolio 116% to $204M in the latest quarter. Management consistently emphasizes growth in these key product lines and the financials show delivering growth across the portfolio.
“Total net sales for Q1 2026 increased 20% driven by Jakafi, Opzelura, and Hematology/Oncology portfolio.”
“Total net product revenue for Q4 2025 increased 20% driven by Jakafi, Opzelura, Niktimvo, and Zynyz.”
“Net product revenues increased 19% driven by Jakafi and strong uptake of Niktimvo.”
“Jakafi net product revenues up 8% and Niktimvo net product revenues demonstrate strong commercial execution.”
“Jakafi net product revenues up 24% and Niktimvo launched with strong execution.”
“Jakafi net revenues up 11% and Opzelura net revenues up 48% in Q4 2024.”